Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin plus pembrolizumab versus platinum-gemcitabine chemotherapy in previously untreated advanced urothelial cancer
2023-503421-19-00Phase 3Authorised
- Sponsor
- Seagen Inc.
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Seagen Inc. Primary endpoints: Progression-free survival and Overall survival. Planned start Aug 2020; status: authorised.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-503421-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503421-19-00.